1. Dosage form containing 25 to 400 mg of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl ) benzoic acid. ! 2. The dosage form according to claim 1, where the amount of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl ) benzoic acid is from 100 to 300 mg. ! 3. The dosage form according to claim 1, where the amount of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl ) benzoic acid is 200 mg. !four. The dosage form according to any one of claims 1 to 3, wherein 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2- il) benzoic acid is characterized by the presence of one or more peaks in the range from 15.2 to 15.6 °, from 16.1 to 16.5 °, and from 14.3 to 14.7 ° in the powder X-ray diffraction pattern using alpha radiation CuK. ! 5. The dosage form according to claim 4, where 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) Benzoic acid is characterized by one or more peaks at angles of approximately 15.4 °, 16.3 ° and 14.5 °. ! 6. The dosage form according to claim 4, where 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid is additionally characterized by a peak in the range from 14.6 ° to 15.0 °. ! 7. The dosage form according to claim 4, where 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid is additionally characterized by a peak at 14.8 °. ! 8. The dosage form according to claim 4, where 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) be�1. Дозированная лекарственная форма, содержащая от 25 до 400 мг 3-(6-(1-(2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты. ! 2. Дозированная лекарственная
